Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Fecal Microbiota Transplantation (Rambam Health Care Campus)
- Development stage
- Unknown
- Lead developer
- Rambam Health Care Campus
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Nasogastric
01
Overview
Autologous fecal microbiota transplantation (FMT) is an experimental microbial therapy being developed by the Rambam Health Care Campus for the treatment of acute steroid-resistant gastrointestinal graft-versus-host disease (GI-GVHD). The procedure involves the collection and cryopreservation of a patient's own fecal matter prior to undergoing allogeneic hematopoietic stem cell transplantation (Allo-SCT). If the patient subsequently develops severe GI-GVHD, the stored autologous sample is processed into a standardized suspension and re-introduced via a nasogastric tube. This approach aims to restore the patient's baseline gut microbial diversity and composition, which are typically decimated by conditioning chemotherapy and broad-spectrum antibiotics, thereby mitigating the inflammatory response and promoting mucosal healing without the infectious risks associated with third-party donor FMT.
- Other names
- Autologous Fecal Microbiota TransplantationAutologous FMTAuto-FMT
Beyond the preview
Go deeper on Autologous Fecal Microbiota Transplantation (Rambam Health Care Campus).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Fecal Microbiota Transplantation (Rambam Health Care Campus).